Galapagos | Passività Correnti



Current Liabilities Cambiamento Data
AstraZeneca USD 27.87B 1.94B 2024-12
Biogen USD 5.53B 103.8M 2024-12
Genmab DKK 5.31B 723M 2024-12
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
GRIFOLS EUR 2.16B 199.43M 2024-12
Hikma Pharmaceutical USD 1.38B 41M 2024-06
Incyte USD 1.64B 140.2M 2024-12
Merck EUR 10.46B 532M 2024-09
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 30.03B 5.82B 2024-06
UCB EUR 3.53B 731M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Galapagos Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.